REPRODUCTIVE PLANNING FOR WOMEN USING GLP-1 AGONISTS: AN INTEGRATIVE REVIEW
DOI:
https://doi.org/10.36557/2674-8169.2026v8n8p1574-1594Keywords:
GLP-1 agonists, reproductive planning, women's health, contraception, fertility, obesity.Abstract
The use of glucagon-like peptide-1 (GLP-1) receptor agonists has increased among women of reproductive age, primarily for the treatment of obesity, type 2 diabetes mellitus, and metabolic disorders associated with insulin resistance. Given this context, the potential impact of these therapies on fertility, contraception, and pregnancy planning is a matter of importance. This study aimed to analyze the available scientific evidence regarding reproductive planning for women using GLP-1 agonists. It is an integrative literature review based on studies published between 2018 and 2026, selected from national and international scientific databases. The results demonstrated that these medications offer significant benefits regarding glycemic control, body weight reduction, and the improvement of insulin resistance. In women with polycystic ovary syndrome, these effects may contribute to greater menstrual regularity and the restoration of ovulation, thereby increasing the likelihood of pregnancy. However, evidence regarding safety during pregnancy remains limited, underscoring the need for effective contraception and the discontinuation of treatment prior to planned conception. The study concludes that reproductive planning should be an integral part of the care provided to women of childbearing age using GLP-1 agonists, involving individualized guidance on fertility, contraception, and the preconception period.
Downloads
References
AMERICAN DIABETES ASSOCIATION PROFESSIONAL PRACTICE COMMITTEE FOR DIABETES. 8. Obesity and weight management for the prevention and treatment of diabetes: Standards of Care in Diabetes—2026. Diabetes Care, v. 49, supl. 1, p. S166-S182, 2026. DOI: 10.2337/dc26-S008.
BECKER, A. S.; CASTILHOS, J. P.; SHUGAIR, S. A. S.; COLOMBO, T.; HENTSCHKE, M. R. GLP-1 receptor agonists and fertility: what is known so far? JBRA Assisted Reproduction, 2026. Publicação antecipada on-line. DOI: 10.5935/1518-0557.20260028.
DAO, K. et al. Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open, v. 14, n. 4, e083550, 2024. DOI: 10.1136/bmjopen-2023-083550.
FRÍAS, J. P. et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, v. 385, p. 503-515, 2021. DOI: 10.1056/NEJMoa2107519.
GOLDBERG, A. S.; BOOTS, C. E. Treating obesity and fertility in the era of glucagon-like peptide 1 receptor agonists. Fertility and Sterility, v. 122, n. 2, p. 211-218, 2024. DOI: 10.1016/j.fertnstert.2024.05.154.
JASTREBOFF, A. M. et al. Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, v. 387, p. 205-216, 2022. DOI: 10.1056/NEJMoa2206038.
LIU, Q. K. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists. Frontiers in Endocrinology, v. 15, art. 1431292, 2024. DOI: 10.3389/fendo.2024.1431292.
MASLIN, K. et al. What is known about the use of weight loss medication in women with overweight/obesity on fertility and reproductive health outcomes? A scoping review. Clinical Obesity, v. 14, n. 6, e12690, 2024. DOI: 10.1111/cob.12690.
MENDES, K. D. S.; SILVEIRA, R. C. C. P.; GALVÃO, C. M. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem, Florianópolis, v. 17, n. 4, p. 758-764, 2008.
MULLER, D. R. P.; STENVERS, D. J.; MALEKZADEH, A.; HOLLEMAN, F.; PAINTER, R. C.; SIEGELAAR, S. E. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence. Frontiers in Endocrinology, v. 14, art. 1215356, 2023. DOI: 10.3389/fendo.2023.1215356.
PRICE, S. A. L.; NANKERVIS, A. Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review. Archives of Gynecology and Obstetrics, v. 311, n. 5, p. 1241-1247, 2025. DOI: 10.1007/s00404-024-07849-9.
ROSEN, C. J.; INGELFINGER, J. R. GLP-1 receptor agonists. The New England Journal of Medicine, v. 394, n. 13, p. 1313-1324, 2026. DOI: 10.1056/NEJMra2500106.
TEEDE, H. J. et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertility and Sterility, v. 120, n. 4, p. 767-793, 2023. DOI: 10.1016/j.fertnstert.2023.07.025.
WHITTEMORE, R.; KNAFL, K. The integrative review: updated methodology. Journal of Advanced Nursing, v. 52, n. 5, p. 546-553, 2005. DOI: 10.1111/j.1365-2648.2005.03621.x.
ZHOU, L.; QU, H.; YANG, L.; SHOU, L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocrine Disorders, v. 23, art. 245, 2023. DOI: 10.1186/s12902-023-01500-5.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Maria Eduarda Bezerra do Nascimento, Ana Beatriz Oliveira de Melo, Lorena Gonçalves Lobato , Ramon Oliveira Cameli , Fernanda Calumby Nóbrega Guimarães, Isadora Fortes Sampaio Juchem , Thaís Rodrigues Ferreira , João Victor Oliveira Andrade, Paula Marinho Borges, Jéssica Alessandra Pereira , Pedro Marcos de Melo Teixeira , Karolyne Alvarez Bispo
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors are copyright holders under a CCBY 4.0 license.
